Driving forces behind increasing cardiovascular drug utilization: A dynamic pharmacoepidemiological model

British Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2008, Pages 885-895

  Kildemoes, Helle Wallach ^a   Støvring, Henrik ^a   Andersen, Morten ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cardiovasculardrugs; Driving forces; Drug utilization analysis; Pharmacoepidemiological model; Population ageing

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POTASSIUM SPARING DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGED; AGING; ANALYTIC METHOD; ARTICLE; CARDIOVASCULAR SYSTEM; CONFIDENCE INTERVAL; DATA BASE; DENMARK; DRUG UTILIZATION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACOEPIDEMIOLOGY; PREVALENCE; PRIORITY JOURNAL; REGISTER; STANDARDIZATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; DENMARK; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PREVALENCE; YOUNG ADULT;

EID: 56549106301     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03282.x     Document Type: Article

References (40)

1. Gerdtham UG, Lundin D. Why did drug spending increase during the 1990s? A decomposition based on Swedish data. Pharmacoeconomics 2004 22 : 29 42.
2. Morgan SG. Prescription drug expenditures and population demographics. Health Serv Res 2006 41 : 411 28.
3. Morgan SG. Booming prescription drug expenditure: a population-based analysis of age dynamics. Med Care 2005 43 : 996 1008.
4. Evans RG, McGrail KM, Morgen SG, Barer ML, Hertzman C. APOCALYPSE NO: population aging and the future of health care systems. Can J Aging 2001 20 : 160 91.
5. Kildemoes HW, Christiansen T, Gyrd-Hansen D, Kristiansen IS, Andersen M. The impact of population ageing on future Danish drug expenditure. Health Policy 2006 75 : 298 311.
6. Breyer F, Felder S. Life expectancy and health care expenditures: a new calculation for Germany using the costs of dying. Health Policy 2006 75 : 178 86.
7. Anderson GM, Kerluke KJ, Pulcins IR, Hertzman C, Barer ML. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program. Inquiry 1993 30 : 199 207.
8. Reinhardt UE. Does the aging of the population really drive the demand for health care? Health Affairs 2003 22 : 27 39.
9. Jackevicius CA, Tu K, Filate WA, Brien SE, Tu JV. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J Cardiol 2003 19 : 1359 66.
10. Barer ML, Evans RG, Hertzman C. Avalanche or glacier - health-care and the demographic rhetoric. Can J Aging 1995 14 : 193 224.
11. Dubois RW, Chawla AJ, Neslusan CA, Smith MW, Wade S. Explaining drug spending trends: does perception match reality? Health Aff (Millwood) 2000 19 : 231 9.
12. Van Tielen R, Peys F, Genaert J. The demographic impact on ambulatory pharmaceutical expenditure in Belgium. Health Policy 1998 45 : 1 14.
13. Medical Products Statistics 2000-2005. Copenhagen, Denmark : The Danish Medicines Agency, 2006.
14. Medical Products Statistics 1996-2000. Copenhagen, Denmark : The Danish Medicines Agency, 2001.
15. Hallas J, Gaist D, Bjerrum L. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 1997 8 : 666 70.
16. Hallas J, Stovring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol 2006 98 : 260 5.
17. Stovring H, Andersen M, Beck-Nielsen H, Green A, Vach W. Counting drugs to understand the disease: the case of measuring the diabetes epidemic. Popul Health Metr 2007 5 : 2.
18. WHO Collaborating Centre for Drug Statistics Methodology (ed.). Guidelines for ATC Classification and DDD Assignment 2005. Oslo, Norway : WHO, 2004.
19. Merlo J, Ranstam J, Rastam L, Wessling A, Melander A. Age standardisation of drug utilisation: comparisons of different methods using cardiovascular drug data from Sweden and Spain. Eur J Clin Pharmacol 1994 46 : 393 8.
20. Keiding N. Age-specific incidence and prevalence - a statistical perspective. J R Stat Soc Ser A Stat Soc 1991 154 : 371 412.
21. Rothman KJ, Greenland S. Modern Epidemiology, 2nd edn. Philadelphia, PA : Lippincott-Raven Publishers, 1998.
22. Breslow NE, Day NE. Indirect Standardization and multiplicative models for rates, with reference to age adjustment of cancer incidence and relative frequency data. J Chron Dis 1975 28 : 289 303.
23. Morgan S. Drug spending in Canada: recent trends and causes. Med Care 2004 42 : 635 42.
24. Gerdtham U, Lundin D. Changes in drug spending for different age groups during the 1990s. Evidence from Sweden. Expert Rev Pharmacoeconomics Outcome Res 2004 4 : 343 51.
25. Walley T, Folino-Gallo P, Stephens P, Van GE. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005 60 : 543 51.
26. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004 19 : 638 45.
27. Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000 49 : 463 71.
28. Yang Z, Norton EC, Stearns SC. Longevity and health care expenditures: the real reasons older people spend more. J Gerontol B Psychol Sci Soc Sci 2003 58B : S2 10.
29. Bouchard MH, Dragomir A, Blais L, Berard A, Pilon D, Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007 63 : 698 708.
30. Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005 59 : 564 73.
31. Hallas J. Drug utilization statistics for individual-level pharmacy dispensing data. Pharmacoepidemiol Drug Saf 2005 14 : 455 63.
32. Schroll H, Stovring H, Houmand A, Kragstrup J. Estimating incidence and prevalence of episodes of care in general practice. Scand J Prim Health Care 2004 22 : 60 4.
33. Stovring H, Vach W. Estimation of prevalence and incidence based on occurrence of health-related events. Stat Med 2005 24 : 3139 54.
34. Bjerrum L, Rosholm JU, Hallas J, Kragstrup J. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 1997 53 : 7 11.
35. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002 53 : 375 8.
36. Perreault S, Lamarre D, Blais L, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005 39 : 1401 8.
37. Marceau C, Lemiere C, Berbiche D, Perreault S, Blais L. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol 2006 118 : 574 81.
38. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007 297 : 177 86.
39. Videbaek J, Madsen M (eds). Heart Statistics 2004. Copenhagen : Danish Heart Foundation; National Institute of Public Health, 2004.
40. Stovring H. Selection bias due to immigration in pharmacoepidemiologic studies. Pharmacoepidemiol Drug Saf 2007 16 : 681 6.